Agnieszka Paradowska-Gorycka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4430390/publications.pdf

Version: 2024-02-01

72 papers

1,061 citations

430874 18 h-index 29 g-index

74 all docs

74 docs citations

74 times ranked 1833 citing authors

#	Article	IF	CITATIONS
1	ILâ€23 in the Pathogenesis of Rheumatoid Arthritis. Scandinavian Journal of Immunology, 2010, 71, 134-145.	2.7	87
2	Association between ILâ€17F Gene Polymorphisms and Susceptibility to and Severity of Rheumatoid Arthritis (RA). Scandinavian Journal of Immunology, 2010, 72, 134-141.	2.7	82
3	Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. Human Immunology, 2013, 74, 730-737.	2.4	75
4	Th17/Treg-Related Transcriptional Factor Expression and Cytokine Profile in Patients With Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 572858.	4.8	65
5	Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice. Cells, 2020, 9, 1127.	4.1	51
6	The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. International Journal of Molecular Sciences, 2021, 22, 2922.	4.1	49
7	Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2015, 16, 24194-24218.	4.1	37
8	CD28, CTLA-4 and CCL5 gene polymorphisms in patients with rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 1129-1135.	2.2	34
9	Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0160769.	2.5	32
10	Interleukinâ€10 gene promoter polymorphism in Polish rheumatoid arthritis patients. International Journal of Immunogenetics, 2010, 37, 225-231.	1.8	31
11	Association of Single Nucleotide Polymorphisms in the <i><i><i><scp>IL</scp>27</i></i> Arthritis. Scandinavian Journal of Immunology, 2014, 80, 298-305.</i>	2.7	30
12	Cytokines in the pathogenesis of hemophilic arthropathy. Cytokine and Growth Factor Reviews, 2018, 39, 71-91.	7.2	30
13	miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis. Cells, 2022, 11, 452.	4.1	28
14	Association of HLAâ€DRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients. Hla, 2016, 87, 13-18.	0.6	24
15	Genetic Polymorphisms of <i>Foxp3</i> in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 170-180.	2.0	22
16	The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 41-55.	3.3	22
17	The Interplay between Transcriptional Factors and MicroRNAs as an Important Factor for Th17/Treg Balance in RA Patients. International Journal of Molecular Sciences, 2020, 21, 7169.	4.1	22
18	Genetic Variants in <i><scp>IL</scp>â€12B</i> and <i><scp>IL</scp>â€27</i> in the Polish Patients with Systemic Lupus Erythematosus. Scandinavian Journal of Immunology, 2016, 84, 49-60.	2.7	21

#	Article	IF	CITATIONS
19	Significance of Omega-3 Fatty Acids in the Prophylaxis and Treatment after Spinal Cord Injury in Rodent Models. Mediators of Inflammation, 2020, 2020, 1-11.	3.0	19
20	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Scientific Reports, 2018, 8, 7342.	3.3	18
21	The Serum Cell-Free microRNA Expression Profile in MCTD, SLE, SSc, and RA Patients. Journal of Clinical Medicine, 2020, 9, 161.	2.4	18
22	<scp>IL</scp> â€12B Gene Polymorphisms and <scp>IL</scp> â€12 p70 Serum Levels Among Patients with Rheumatoid Arthritis. Scandinavian Journal of Immunology, 2017, 85, 147-154.	2.7	15
23	Variety of endosomal TLRs and Interferons (IFNâ€Î±, IFNâ€Î², IFNâ€Î³) expression profiles in patients with SLE, SSc and MCTD. Clinical and Experimental Immunology, 2021, 204, 49-63.	2.6	15
24	Interleukin 1 Beta (IL1beta) Gene Polymorphisms (SNP-511 and SNP+3953) in Hashimoto's Thyroiditis among the Polish Population. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, 544-547.	1.2	14
25	Personalized medicine in rheumatology. Reumatologia, 2016, 54, 177-186.	1.1	14
26	Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 539-545.	2.0	14
27	IL-35, TNF-α, BAFF, and VEGF serum levels in patients with different rheumatic diseases. Reumatologia, 2019, 57, 145-150.	1.1	14
28	Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy. International Journal of Molecular Sciences, 2022, 23, 2366.	4.1	14
29	KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis. Biomolecules, 2019, 9, 355.	4.0	13
30	Impact of the <i>IL-23</i> and <i>IL-23R</i> on susceptibility and phenotype of systemic lupus erythematosus. Autoimmunity, 2016, 49, 373-382.	2.6	12
31	Epigenetics: The Future Direction in Systemic Sclerosis. Scandinavian Journal of Immunology, 2017, 86, 427-435.	2.7	11
32	U1-RNP and TLR receptors in the pathogenesis of mixed connective tissue disease. Part I. The U1-RNP complex and its biological significance in the pathogenesis of mixed connective tissue disease. Reumatologia, 2015, 53, 94-100.	1.1	10
33	Epigenetic Regulations of AhR in the Aspect of Immunomodulation. International Journal of Molecular Sciences, 2020, 21, 6404.	4.1	10
34	Interleukin 21 gene polymorphism rs2221903 is associated with disease activity in patients with rheumatoid arthritis. Archives of Medical Science, 2017, 5, 1142-1147.	0.9	9
35	Association of the Smad3 and NFATc2 gene polymorphisms and their serum levels with susceptibility to rheumatoid arthritis in Polish cohorts. Clinical and Experimental Immunology, 2015, 179, 444-453.	2.6	8
36	IL-10, IL-12B and IL-17 gene polymorphisms in patients with mixed connective tissue disease. Modern Rheumatology, 2015, 25, 487-489.	1.8	8

#	Article	IF	CITATIONS
37	U1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue disease Part II. Endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease. Reumatologia, 2015, 53, 143-151.	1.1	7
38	HIF-1A gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case–control study. Inflammation Research, 2018, 67, 423-433.	4.0	7
39	The Role of MECP2 and CCR5 Polymorphisms on the Development and Course of Systemic Lupus Erythematosus. Biomolecules, 2020, 10, 494.	4.0	7
40	miR-10 and Its Negative Correlation with Serum IL-35 Concentration and Positive Correlation with STAT5a Expression in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences, 2022, 23, 7925.	4.1	7
41	Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome. Reumatologia, 2016, 54, 187-195.	1.1	6
42	Lack of association between rheumatoid arthritis and genetic variants rs10889677, rs11209026 and rs2201841 of IL-23R gene. Medicina ClÃnica, 2018, 151, 191-195.	0.6	6
43	FLT-1 gene polymorphisms and protein expression profile in rheumatoid arthritis. PLoS ONE, 2017, 12, e0172018.	2.5	6
44	Discrepancies in assessment of patients with rheumatoid arthritis and secondary Sjögren's syndrome by DAS28-ESR and DAS28-CRP. Central-European Journal of Immunology, 2016, 2, 188-194.	1.2	5
45	VAV1 Gene Polymorphisms in Patients with Rheumatoid Arthritis. International Journal of Environmental Research and Public Health, 2020, 17, 3214.	2.6	5
46	The level of TGF-b in sera of patients with primary Sjögren's syndrome. Reumatologia, 2019, 57, 309-314.	1.1	4
47	RORC2 Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences, 2016, 17, 488.	4.1	3
48	Application of NGS Technology in Understanding the Pathology of Autoimmune Diseases. Journal of Clinical Medicine, 2021, 10, 3334.	2.4	3
49	Association study between immune-related miRNAs and mixed connective tissue disease. Arthritis Research and Therapy, 2021, 23, 19.	3.5	3
50	AB0003â€Relationship Between Vegfa Gene Polymorphisms and Serum Vegf Protein Levels in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 892.1-892.	0.9	2
51	SLC22A5 polymorphism associated with risk of extra-articular manifestations in rheumatoid arthritis patients. Reumatologia, 2019, 57, 3-7.	1.1	2
52	Interferons (IFN-A/-B/-G) Genetic Variants in Patients with Mixed Connective Tissue Disease (MCTD). Journal of Clinical Medicine, 2019, 8, 2046.	2.4	2
53	Mesenchymal stem cells in systemic sclerosis therapy. Reumatologia, 2020, 58, 324-330.	1.1	2
54	The role of cell-free circulating microRNA in diagnostics in patients with rheumatoid arthritis. Reumatologia, 2016, 3, 95-96.	1.1	1

#	Article	IF	Citations
55	SATO195â€Early Nailfold Capillaroscopic Pattern Predominates in Patients with Mixed Connective Tissue Disease. Annals of the Rheumatic Diseases, 2016, 75, 738.3-738.	0.9	1
56	Lack of significant association between selected STAT3 polymorphisms and rheumatoid arthritis in the Polish population. Reumatologia, 2018, 56, 73-79.	1.1	1
57	Association of human papillomavirus with breast cancer: a new perspective on an old debate. Future Oncology, 2022, 18, 2483-2494.	2.4	1
58	FRIO452â€Predictors of Pulmonary Arterial Hypertension in 79 Patients with Mixed Connective Tissue Disease. Annals of the Rheumatic Diseases, 2015, 74, 591.2-591.	0.9	0
59	SATO468 Disease Activity and Damage in Patients with Mixed Connective Tissue Disease (MCTD). Annals of the Rheumatic Diseases, 2015, 74, 830.1-830.	0.9	O
60	AB0002â€The Relation of Rorc Gene Polymorphisms on Severity of Rhemumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 891.2-892.	0.9	0
61	SAT0049â€Serum Concentrations of OPG and Rankl in Rheumatoid Arthritis in Different Biologic Therapies. Annals of the Rheumatic Diseases, 2015, 74, 665.3-666.	0.9	O
62	AB0586â€Predictors of Interstitial Lung Disease in 79 Patients with Mixed Connective Tissue Disease. Annals of the Rheumatic Diseases, 2016, 75, 1105.1-1105.	0.9	0
63	AB0275â€Differences in The Clinical Evaluation of Joints in Patients with Rheumatoid Arthritis and Secondary Sjögren Syndrome. Annals of the Rheumatic Diseases, 2016, 75, 993.3-994.	0.9	O
64	AB0002â€Genetic Variants in IL-17F, IL-23 and IL-23R in The Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 897.2-897.	0.9	0
65	AB0001â€Genetic Variants in IL-12B and IL-27 in The Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 897.1-897.	0.9	0
66	THU0012â€HLA-DBR1 alleles profile in patients with rheumatoid arthritis: relation to disease susceptibility and severity. , 2017, , .		0
67	THU0271â€SERUM LEVELS OF TRANSFORMING GROWTH FACTOR î' (TGF-î') IN PATIENTS WITH PI SJÖGREN'S SYNDROME. , 2019, , .	RIMARY	0
68	AB0775â \in Characteristics of patients with scleroderma (SSC) treated with various drugs in the clinical assessment and tgf \hat{l} and il13 concentration in comparison to the healthy group., 2018,,.		0
69	FRIO429â€Distinct clinical and immunological picture of mctd patients with skin involvement. , 2018, , .		O
70	How the gut microbiota contributes to changes of autoimmune phenotype – from molecular studies to clinical utility. Reumatologia, 2020, 58, 189-190.	1.1	0
71	THU0277â€THE EXPRESSION OF IFNÎ', INFÎ' AND INFÎ" AND SERUM LEVELS OF THOSE CYTOKINES IN SJÃ−GREN SYNDROME PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 365.1-365.	l'S 0.9	O
72	AB0603â€PDGFÎ AS A POTENTIAL BLOOD MARKER IN DSSC. Annals of the Rheumatic Diseases, 2020, 79, 1598.3-1598.	0.9	0